Pharma Stocks — Analysis & Key Financial Data
Pharma Stocks focus on companies that operate in a specific niche or sub‑industry, where business models, risk drivers, and valuation frameworks tend to rhyme more closely with each other than with the broader market. Grouping stocks by theme makes it easier to understand how fundamentals and pricing compare inside the same opportunity set. On this page you can review pharma stocks with Investment Scores, base valuations, and key financial metrics on Invest Viable. The tag is a transparent grouping tool — a way to organise research around a theme — rather than a recommendation list, so you can still apply your own judgement and valuation work.
- Stocks matching
- 3,190
- Latest data
- 2026-06-28
Highest Investment Scores in Pharma Stocks
Top-rated stocks by Investment Score
- Price
- $91.19
- Fair Value
- $355.29
- Market Cap
- $21.2B
- Margin
- +289.6%
- Price
- $175.25
- Fair Value
- $263.72
- Market Cap
- $2.3B
- Margin
- +50.5%
- Price
- $41.36
- Fair Value
- $55.84
- Market Cap
- $1.1B
- Margin
- +35.0%
- Price
- $72.34
- Fair Value
- $69.18
- Market Cap
- $5.1B
- Margin
- -4.4%
Pharma Stock List
| Company | Price | Fair Value | Score | Market Cap | P/E | EPS | Yield |
|---|---|---|---|---|---|---|---|
Adicet Bio, Inc. ACET | $8.64 | — | 26 | $78M | -0.6 | $-10.13 | 0.00% |
Z Squared Inc. ZSQR | $10.58 | — | 19 | $78M | -5.1 | $-1.95 | 0.00% |
Total Return Securities Fund SWZ | $5.94 | — | 77 | $77M | 4.3 | $1.13 | 0.00% |
Elicio Therapeutics, Inc. ELTX | $3.91 | — | 16 | $76M | -1.7 | $-2.21 | 0.00% |
DLH Holdings Corp. DLHC | $5.25 | $11.52 | 42 | $76M | -16.6 | $-0.31 | 0.00% |
Happy City Holdings Limited Class A Ordinary shares HCHL | $3.96 | — | 3 | $76M | -31.0 | $-0.13 | 0.00% |
Quantum X Labs Inc. QXL | $5.70 | — | 3 | $76M | -2.9 | $-1.41 | 0.00% |
Nano-X Imaging Ltd. NNOX | $1.16 | — | 29 | $76M | -1.0 | $-1.09 | 0.00% |
Spruce Biosciences, Inc. SPRB | $54.00 | — | 29 | $76M | -1.5 | $-27.11 | 0.00% |
American Vanguard Corporation AVD | $2.80 | $8.16 | 26 | $75M | -1.7 | $-1.59 | 0.00% |
Gambling.com Group Ltd GAMB | $1.90 | $18.66 | 42 | $75M | -1.6 | $-1.29 | 0.00% |
BARK, Inc. BARK | $9.98 | — | 23 | $75M | -1.9 | $-4.52 | 0.00% |
OFS Credit Company, Inc. OCCI | $2.56 | — | 35 | $75M | -2.1 | $-1.20 | 43.92% |
Gain Therapeutics, Inc. GANX | $2.03 | — | 26 | $75M | -3.0 | $-0.50 | 0.00% |
Kestrel Group Ltd KG | $9.00 | — | 35 | $74M | 0.8 | $5.12 | 0.00% |
Anfield Energy Inc. Common Shares AEC | $4.37 | — | 16 | $74M | -3.8 | $-1.38 | 0.00% |
NeoVolta Inc NEOV | $3.15 | — | 19 | $74M | -6.5 | $-0.29 | 0.00% |
Datacentrex, Inc. DTCX | $1.78 | — | 32 | $73M | -4.4 | $-0.41 | 0.00% |
Verrica Pharmaceuticals Inc. VRCA | $6.12 | — | 32 | $73M | -4.4 | $-1.67 | 0.00% |
eXoZymes, Inc. EXOZ | $8.43 | — | 19 | $73M | -7.0 | $-1.14 | 0.00% |
Edesa Biotech, Inc. EDSA | $8.13 | — | 29 | $73M | -6.1 | $-1.27 | 0.00% |
JFB Construction Holdings Class A Common Stock JFB | $4.81 | — | 35 | $72M | -8.3 | $-0.65 | 0.00% |
Heidmar Maritime Holdings Corp. HMR | $1.28 | — | 52 | $72M | -5.6 | $-0.21 | 0.00% |
VisionWave Holdings, Inc. VWAV | $4.30 | — | 10 | $72M | -2.5 | $-1.66 | 0.00% |
Advanced Flower Capital Inc. AFCG | $3.10 | $18.32 | 39 | $71M | -4.9 | $-0.57 | 11.18% |
About pharma stocks
Pharma is the mature, commercial-stage end of healthcare therapeutics. Large drug manufacturers operate diversified product portfolios across therapeutic areas, with cash flow that is unusually predictable for the broader Healthcare sector — until a major drug approaches its patent cliff and the loss-of-exclusivity timing starts to matter. Specialty pharma operates on similar conventions in narrower therapeutic areas, while generic manufacturers run on much thinner margins and faster product cycles.
The screener treats all of them through the same valuation pipeline. The Investment Score's emphasis on profitability and balance-sheet quality lands cleanly here because most pharma names generate substantial free cash flow and carry manageable leverage. The page surfaces the supporting metrics — growth, yield, the three margin-of-safety variants — so the picture isn't reduced to a single ratio. The Biotech page is the place to look for clinical-stage and pre-revenue therapeutics names that don't fit the standard pharma profile.
What this page is for
This page is a screener and reference surface, not editorial coverage. The list above refreshes with each data update; the methodology, FAQ, and related categories below stay in place so the page is useful both for somebody arriving from a specific search and for somebody scanning the industry for the first time.
If you want to value a single pharma stock end-to-end rather than scan the industry, the Invest Viable Valuator walks through the same models we use to compute the base valuations on this page.
Where you'll find Pharma Stocks
This theme typically shows up across the sectors below. Each sector page lists every covered name with the same Investment Score model and base-valuation pipeline.
How we screen Pharma Stocks
A company appears on this page when its primary industry classification is Pharmaceuticals — typically large commercial-stage drug manufacturers with marketed portfolios.
- Listed on a US exchange (NYSE / Nasdaq) and classified as Pharmaceuticals or Drug Manufacturers in our industry taxonomy.
- Includes Big Pharma, specialty pharma, generic manufacturers, and animal-health drug specialists. Pre-revenue clinical-stage names sit on the dedicated Biotech Stocks page.
- Investment Score and base valuation computed by the same models used elsewhere on Invest Viable.
Frequently asked questions
How is Pharma different from Biotech?
Pharma is dominated by commercial-stage drugmakers with established revenue, marketed portfolios, and patent-cliff calendars. Biotech is heavier on clinical-stage and recently-commercialised names where revenue is small or zero and value depends on pipeline outcomes. Both pages cover therapeutic developers, but the financial profiles inside each are very different.
How are pharma stocks valued?
Mature pharma is typically valued like a stable industrial — DCF on free cash flow, multiples on earnings — with adjustments for patent-cliff timing on key products. Pipeline value is added on top through probability-weighted scenarios. Our base valuations apply the standard methods; pipeline-specific adjustments require the dedicated Valuator workflow.
Why do pharma yields tend to be high?
Mature pharma businesses generate substantial free cash flow and have historically returned a large share through dividends and buybacks. The yield isn't automatic — patent-cliff exposure, R&D reinvestment requirements, and balance-sheet position all affect coverage. The screener surfaces yield alongside Investment Score so the profile is visible.
Are generics included on this page?
Yes when their primary classification is Pharmaceuticals. Generics manufacturers operate on different unit economics than branded pharma — much lower margins, faster product cycles — but share the industry classification and financial conventions.
Does Invest Viable recommend specific pharma stocks?
No. This page is a screener and analysis surface, not a recommendation list. Each stock is shown with its underlying financial data, base valuation, and Investment Score so you can do your own research. Invest Viable does not publish buy or sell calls on individual securities.